ANN ARBOR — Everist Genomics announced Friday that its
executive vice chairman, Alex Charlton, will speak about its
breakthrough CardioDefender Device at the Wearable Technologies
Conference Monday in Munich, Germany.

Smartphone healthcare applications are graduating from novelty
items to mainstream medicine, helping physicians to save lives
and reduce the cost of care.

Everist Genomics, a rapidly growing personalized medicine
company, is successfully integrating smartphone and tablet
computer technology with innovative, medically important
diagnostics and prognostics in the areas of cardiovascular
disease, diabetes and cancer.

Everist Genomics’ CardioDefender is the world’s first
FDA-approved and CE mark-registered smartphone ECG system to
provide physicians and patients with hospital-quality heart
rhythm monitoring outside of the hospital setting.

CardioDefender incorporates several unique capabilities
enabling physicians to diagnose and treat potentially
life-threatening heart arrhythmias that might otherwise be
missed.

CardioDefender is the first system to deliver mobile,
real-time, beat-by-beat, and quantitative heart monitoring and
automated reporting by combining patented analytical smartphone
software with a Wi-Fi device and electrodes.

“The essence of personalized medicine is to diagnose a problem
before there are noticeable symptoms,” Charlton said.
“Physicians who diagnose and treat heart arrhythmias have been
hampered for many years by legacy technology, such as hospital
based ECG systems which confine patients to the high-cost
hospital setting and Holter monitors which do not provide
the comprehensive monitoring needed to detect potentially life
threatening arrhythmias. For the first time, CardioDefender
enables smartphone-based hospital-quality ECG monitoring of
patients 24 hours per day, seven days per week.”

The company’s recently announced commercialization plans of
CardioDefender coincide with reports from various industry
sources projecting significant growth in remote patient
monitoring. According to analyst firm Berg Insight, for
example, around 2.2 million patients worldwide were using home
monitoring service based on equipment with integrated
connectivity at the end of 2011 — cardiac arrhythmia was cited
as one of the most common conditions monitored by these
technologies.

Following FDA approval and European CE Mark registration last
year, CardioDefender has already been deployed at more
than 150 medical facilities in the United States for
post-approval commercial evaluation. Between January and
October of 2011, the number of patient days of heart rhythm
monitoring performed with CardioDefender grew from fewer than
5,000 to more than 18,000 patient days per month. Since the
system was introduced, Everist Genomics has received inquiries
about the product from more than 32 countries, including China,
India and the United States.

Everist Genomics launched its first product last year with the
introduction of OncoDefender-CRC, a prognostic test for
predicting the risk of disease recurrence for early stage
colorectal cancer patients. The company expanded its pipeline
with the creation of a new franchise of diagnostic and
prognostic tests aimed at melding personalized medicine with
mobile health platforms.

In addition to the CardioDefender diagnostic system,
Everist Genomics recently announced development of
AngioDefender, the world’s first tablet computer device capable
of accurately diagnosing atherosclerosis in asymptomatic
patients. The company is developing mobile applications for the
AngioDefender system to extend physician access to vital
patient information and provide clinical support for treatment
planning. The company plans to launch the AngioDefender system
in February 2012.

More at http://www.everistgenomics.com.

Continue reading here:
Smartphone Tech Meets Personalized Medicine: Everist CardioDefender

Comments are closed.